Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREGS: Regulatory B Cells and IL-2 in Multiple Sclerosis
NCT04697407Completed
- Sponsor
- CHU Rennes
- Start
- Mar 2021
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Trial (3 arms), sponsored by CHU Rennes. Primary endpoint: Frequency of Regulatory B Cells in Blood at 1 month. Started Mar 2021; status: completed.
Beyond the preview
Go deeper on NCT04697407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697407.